Immunotherapy with radiation for stomach cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of immunotherapy (a treatment that helps your immune system fight cancer) with radiation therapy for a certain type of stomach or gastroesophageal junction cancer that has a special genetic marker. The goal is to see if this combination is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 80 years old.
- You have been diagnosed with type II or III adenocarcinoma at the junction of the stomach and esophagus, and your tumor has a specific genetic marker (dMMR/MSI-H).
- Your cancer has not spread to distant organs, but may have spread to nearby lymph nodes.
- You have not received any prior cancer treatment for this condition, such as chemotherapy, radiation, or surgery.
- You must be physically active and able to care for yourself (ECOG score of 0 or 1).
- You must have adequate organ function and be willing to use birth control during the study and for a period after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of low-dose radiation, an immunotherapy drug (tirelizumab), and chemotherapy (SOX) given before surgery for locally advanced gastric or gastroesophageal junction cancer. The goal is to see if this approach can shrink tumors more effectively.
This trial is testing a new combination treatment for advanced or metastatic stomach cancer (that is MSS/pMMR and HER2-negative) that has not been treated before. The treatment combines a short course of radiation (targeted to lymph nodes) with first-line therapy and a PD-1 inhibitor (a type of immunotherapy) to see if it can help control the cancer and improve outcomes.
This study tests combining an immunotherapy drug (PD-1 inhibitor) and a medication to boost your immune system (thymalfasin) with standard chemotherapy and radiation before surgery for stage III cancer where the stomach meets the esophagus. The goal is to see if this approach can shrink the tumor and improve outcomes.
This trial tests whether giving immunotherapy (a treatment that helps your immune system fight cancer) along with chemotherapy and radiation before surgery can help shrink tumors in people with stomach cancer at the esophagus-stomach junction. The goal is to see if this approach is safe and effective before the main surgery.
This trial tests a combination of chemotherapy, low-dose radiation, and an immunotherapy drug called tislelizumab for patients with stomach or gastroesophageal junction cancer that has not spread to distant organs. The goal is to see if this combination can shrink tumors and improve outcomes before and after surgery.
This trial tests whether adding a short course of radiation to a combination of chemotherapy and an immunotherapy drug (called a PD-1 inhibitor) before surgery helps shrink tumors and improve outcomes for people with upper stomach or gastroesophageal junction cancer.
Hear when a new Esophagogastric Junction/Gastric Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.